A chronic challenge facing biologic drug discovery companies is the manufacturability of lead candidates. How do you ensure that the most promising hits from Discovery will make it through CMC development efforts? AbSci’s Protein Printing™ technology has revolutionized biomanufacturing and enabled production of high quality, complex therapeutic proteins in E. coli SoluPro®. Full-length antibody hit generation, affinity maturation, and cell line development can be performed within the Protein Printing™ platform, enabling simultaneous protein discovery and biomanufacturability objectives under accelerated timelines. Triage of high-performance hit and lead candidates due to biomanufacturing constraints is no longer necessary due to these breakthrough technologies.
This webinar will be targeted to senior technical staff and business development professionals in the pharmaceutical and biotech industries.
Matthew is a distinguished scientist leading AbSci’s technology development efforts. Before joining AbSci, Matthew’s career focused on protein engineering, recombinant production of therapeutic proteins, and advanced strain engineering techniques leading to improved performance in biotechnology applications.
He obtained his PhD in chemistry from the University of Utah School of Medicine, followed by leadership roles at Synthetic Genomics, where he led efforts to develop novel genome engineering tools and next-generation host platforms for the bioproduction of therapeutics. Matthew joined AbSci in 2018 and has held leadership roles focused on development of novel strains for the production of biotherapeutics.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.